Open-Label, Phase Ib Study of Sintilimab and Linperlisib Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NKTCL)
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Linperlisib (Primary) ; Sintilimab (Primary)
- Indications Extranodal NK-T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 04 Feb 2025 New trial record